スポンサーリンク

Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd. | 論文

• The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage

スポンサーリンク